Evogene Stock Price, News & Analysis (NASDAQ:EVGN)

$3.88 +0.06 (+1.57 %)
(As of 02/18/2018 04:00 PM ET)
Previous Close$3.88
Today's Range$3.75 - $3.94
52-Week Range$2.66 - $5.84
Volume7,747 shs
Average Volume3,650 shs
Market Capitalization$96.56 million
P/E Ratio-4.67
Dividend YieldN/A
Beta0.8

About Evogene (NASDAQ:EVGN)

Evogene logoEvogene Ltd. (Evogene) is a biotechnology company for the improvement of crop productivity. The Company is engaged in developing seed traits for improved yield and abiotic stress tolerance, seed traits for biotic stress resistance, herbicides and bio-stimulants. The Company operates a seed business under its subsidiary Evofuel Ltd. (Evofuel). It operates through two segments. Its Evogene segment develops seed traits, ag-chemical products, and ag-biological products to improve plant performance. The Company's Evofuel segment develops species of the castor bean plant for second generation feedstock for biofuel and other industrial uses. Its Crop Enhancement (CE) division is developing two types of products: CE seed traits, are seed traits having improved yield and abiotic stress tolerance, and ag-biologicals, which focuses on microbial-based bio-stimulants. The Company's Crop Protection (CP) division is developing two types of products: CP seed traits and ag-chemicals.

Receive EVGN News and Ratings via Email

Sign-up to receive the latest news and ratings for EVGN and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Agricultural Biotechnology
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:EVGN
CUSIPN/A
Phone972-8931-1900

Debt

Debt-to-Equity RatioN/A
Current Ratio16.70%
Quick Ratio16.70%

Price-To-Earnings

Trailing P/E Ratio-4.67469879518072
Forward P/E Ratio-5.24
P/E GrowthN/A

Sales & Book Value

Annual Sales$6.54 million
Price / Sales15.28
Cash FlowN/A
Price / CashN/A
Book Value$3.43 per share
Price / Book1.13

Profitability

Trailing EPS($0.83)
Net Income$-19,590,000.00
Net Margins-555.45%
Return on Equity-26.17%
Return on Assets-23.72%

Miscellaneous

Employees240
Outstanding Shares25,750,000

Evogene (NASDAQ:EVGN) Frequently Asked Questions

What is Evogene's stock symbol?

Evogene trades on the NASDAQ under the ticker symbol "EVGN."

How were Evogene's earnings last quarter?

Evogene Ltd (NASDAQ:EVGN) posted its quarterly earnings data on Wednesday, November, 22nd. The biotechnology company reported ($0.20) EPS for the quarter, missing the consensus estimate of ($0.19) by $0.01. The biotechnology company had revenue of $0.75 million for the quarter. Evogene had a negative return on equity of 26.17% and a negative net margin of 555.45%. View Evogene's Earnings History.

When will Evogene make its next earnings announcement?

Evogene is scheduled to release their next quarterly earnings announcement on Wednesday, February, 28th 2018. View Earnings Estimates for Evogene.

Who are some of Evogene's key competitors?

Who are Evogene's key executives?

Evogene's management team includes the folowing people:

  • Martin S. Gerstel, Chairman of the Board (Age 73)
  • Ofer Haviv, President, Chief Executive Officer (Age 47)
  • Alex Taskar, Chief Financial Officer
  • Yuval Ben-Galim, Chief Operating Officer
  • Hagai Karchi, Executive Vice President, Chief Technology Officer (Age 53)
  • Amos Shachar, Vice President of Project Management (Age 39)
  • Lea Slonim Bloom, Director of Administration & Human Resources (Age 43)
  • Sarit Firon, Director
  • Adina Makover, Director (Age 65)
  • Leon Yehuda Recanati, Director (Age 67)

Who owns Evogene stock?

Evogene's stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include MIGDAL INSURANCE & FINANCIAL HOLDINGS LTD. (59.00%), Harel Insurance Investments & Financial Services Ltd. (0.54%) and Jane Street Group LLC (0.33%). View Institutional Ownership Trends for Evogene.

Who bought Evogene stock? Who is buying Evogene stock?

Evogene's stock was purchased by a variety of institutional investors in the last quarter, including Harel Insurance Investments & Financial Services Ltd. and Jane Street Group LLC. View Insider Buying and Selling for Evogene.

How do I buy Evogene stock?

Shares of Evogene can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Evogene's stock price today?

One share of Evogene stock can currently be purchased for approximately $3.88.

How big of a company is Evogene?

Evogene has a market capitalization of $96.56 million and generates $6.54 million in revenue each year. The biotechnology company earns $-19,590,000.00 in net income (profit) each year or ($0.83) on an earnings per share basis. Evogene employs 240 workers across the globe.

How can I contact Evogene?

Evogene's mailing address is 13 GAD FEINSTEIN STREET, REHOVOT L3, 7612002. The biotechnology company can be reached via phone at 972-8931-1900 or via email at [email protected]


MarketBeat Community Rating for Evogene (EVGN)

Community Ranking:  2.4 out of 5 (star star)
Outperform Votes:  60 (Vote Outperform)
Underperform Votes:  67 (Vote Underperform)
Total Votes:  127
MarketBeat's community ratings are surveys of what our community members think about Evogene and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Evogene (NASDAQ:EVGN) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: N/AN/AN/AN/A
Consensus Rating Score: N/AN/AN/AN/A
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: N/AN/AN/AN/A
Price Target Upside: N/AN/AN/AN/A

Evogene (NASDAQ:EVGN) Consensus Price Target History

Price Target History for Evogene (NASDAQ:EVGN)

Evogene (NASDAQ:EVGN) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
8/17/2016Credit Suisse GroupLower Price TargetOutperform$19.00 -> $10.00N/AView Rating Details
(Data available from 2/18/2016 forward)

Earnings

Evogene (NASDAQ:EVGN) Earnings History and Estimates Chart

Earnings by Quarter for Evogene (NASDAQ:EVGN)

Evogene (NASDAQ EVGN) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
2/28/2018($0.18)N/AView Earnings Details
11/22/2017Q3 2017($0.19)($0.20)$0.75 millionViewN/AView Earnings Details
8/10/20176/30/2017($0.13)($0.18)$1.18 millionViewN/AView Earnings Details
5/17/20173/31/2017($0.18)($0.19)$0.72 millionViewN/AView Earnings Details
2/27/2017Q4($0.18)($0.26)$1.18 millionViewListenView Earnings Details
11/21/2016Q3($0.07)($0.20)$1.54 millionViewN/AView Earnings Details
8/11/2016Q2($0.11)($0.18)$5.36 million$3.82 millionViewListenView Earnings Details
5/19/2016Q1($0.11)($0.13)$2.70 million$2.00 millionViewListenView Earnings Details
3/1/2016Q415($0.17)($0.22)$3.90 million$2.46 millionViewN/AView Earnings Details
11/18/2015Q315($0.15)($0.13)$3.50 million$3.31 millionViewListenView Earnings Details
8/5/2015Q215($0.19)($0.20)$4.40 million$2.66 millionViewN/AView Earnings Details
5/19/2015Q115($0.20)($0.13)$3.65 million$2.70 millionViewListenView Earnings Details
2/26/2015Q4($0.12)($0.19)$3.64 millionViewN/AView Earnings Details
11/10/2014Q314($0.10)($0.17)$4.20 million$3.16 millionViewN/AView Earnings Details
8/20/2014Q214($0.11)($0.13)$4.77 million$3.85 millionViewN/AView Earnings Details
5/7/2014Q1 14($0.13)($0.09)$5.40 million$3.86 millionViewN/AView Earnings Details
3/19/2014Q413($0.08)($0.20)$4.95 million$4.41 millionViewN/AView Earnings Details
10/24/2013Q3 2013($0.06)$4.23 millionViewN/AView Earnings Details
8/18/2013Q2 2013($0.05)$4.32 millionViewN/AView Earnings Details
5/13/2013Q1 2013($0.01)$4.62 millionViewN/AView Earnings Details
11/19/2012Q3 2012($0.03)ViewN/AView Earnings Details
8/13/2012Q2 2012($0.03)ViewN/AView Earnings Details
5/14/2012Q1 2012$0.01ViewN/AView Earnings Details
3/19/2012Q4 2011$0.09ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Estimates

Evogene (NASDAQ:EVGN) Earnings Estimates

Current Year EPS Consensus Estimate: $-0.74 EPS
Next Year EPS Consensus Estimate: $-0.44 EPS

Dividends

Dividend History for Evogene (NASDAQ:EVGN)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Evogene (NASDAQ EVGN)

No insider trades for this company have been tracked by MarketBeat.com

Headlines

Evogene (NASDAQ EVGN) News Headlines

Source:
DateHeadline
-$0.18 Earnings Per Share Expected for Evogene Ltd (EVGN) This Quarter-$0.18 Earnings Per Share Expected for Evogene Ltd (EVGN) This Quarter
www.americanbankingnews.com - February 17 at 3:20 PM
Evogene Financial Results for the Fourth Quarter and Full Year 2017 Earnings Announcement ScheduleEvogene Financial Results for the Fourth Quarter and Full Year 2017 Earnings Announcement Schedule
finance.yahoo.com - February 12 at 9:11 AM
Zacks: Brokerages Anticipate Evogene Ltd. (EVGN) to Post -$0.18 Earnings Per ShareZacks: Brokerages Anticipate Evogene Ltd. (EVGN) to Post -$0.18 Earnings Per Share
www.americanbankingnews.com - January 31 at 3:12 PM
Evogene to Participate in Israeli Consortium to Develop Phenotyping Tools and Systems for Precision AgricultureEvogene to Participate in Israeli Consortium to Develop Phenotyping Tools and Systems for Precision Agriculture
finance.yahoo.com - January 29 at 9:22 AM
Zacks: Brokerages Set $8.00 Price Target for Evogene Ltd. (EVGN)Zacks: Brokerages Set $8.00 Price Target for Evogene Ltd. (EVGN)
www.americanbankingnews.com - January 22 at 3:14 PM
Evogene Announces Positive 2nd Year Field Trial Results in Corn Bio-Stimulant Ag-Biologicals ProgramEvogene Announces Positive 2nd Year Field Trial Results in Corn Bio-Stimulant Ag-Biologicals Program
finance.yahoo.com - January 19 at 10:46 AM
-$0.18 EPS Expected for Evogene Ltd. (EVGN) This Quarter-$0.18 EPS Expected for Evogene Ltd. (EVGN) This Quarter
www.americanbankingnews.com - January 14 at 5:32 PM
 Brokerages Set $8.00 Target Price for Evogene Ltd. (EVGN) Brokerages Set $8.00 Target Price for Evogene Ltd. (EVGN)
www.americanbankingnews.com - January 6 at 11:52 AM
ETFs with exposure to Evogene Ltd. : December 27, 2017ETFs with exposure to Evogene Ltd. : December 27, 2017
finance.yahoo.com - December 28 at 9:46 AM
Stocks- U.S. Futures Push Forward as Tax Bill Set for Final VoteStocks- U.S. Futures Push Forward as Tax Bill Set for Final Vote
finance.yahoo.com - December 20 at 9:40 AM
Zacks: Evogene Ltd. (EVGN) Given Consensus Recommendation of "Hold" by BrokeragesZacks: Evogene Ltd. (EVGN) Given Consensus Recommendation of "Hold" by Brokerages
www.americanbankingnews.com - December 13 at 9:18 PM
ETFs with exposure to Evogene Ltd. : December 13, 2017ETFs with exposure to Evogene Ltd. : December 13, 2017
finance.yahoo.com - December 13 at 5:22 PM
Head-To-Head Survey: Evogene (EVGN) vs. Calyxt (CLXT)Head-To-Head Survey: Evogene (EVGN) vs. Calyxt (CLXT)
www.americanbankingnews.com - December 13 at 11:16 AM
 Analysts Anticipate Evogene Ltd. (EVGN) to Post -$0.18 Earnings Per Share Analysts Anticipate Evogene Ltd. (EVGN) to Post -$0.18 Earnings Per Share
www.americanbankingnews.com - December 11 at 5:26 PM
Evogene (EVGN) versus Calyxt (CLXT) Critical ComparisonEvogene (EVGN) versus Calyxt (CLXT) Critical Comparison
www.americanbankingnews.com - December 10 at 3:26 AM
Calyxt (CLXT) vs. Evogene (EVGN) Head to Head ReviewCalyxt (CLXT) vs. Evogene (EVGN) Head to Head Review
www.americanbankingnews.com - December 9 at 6:24 PM
Critical Survey: Evogene (EVGN) & Calyxt (CLXT)Critical Survey: Evogene (EVGN) & Calyxt (CLXT)
www.americanbankingnews.com - December 9 at 5:28 PM
Calyxt (CLXT) vs. Evogene (EVGN) Head-To-Head ContrastCalyxt (CLXT) vs. Evogene (EVGN) Head-To-Head Contrast
www.americanbankingnews.com - December 5 at 3:32 AM
Evogene Ltd. :EVGN-US: Earnings Analysis: Q3, 2017 By the Numbers : December 1, 2017Evogene Ltd. :EVGN-US: Earnings Analysis: Q3, 2017 By the Numbers : December 1, 2017
finance.yahoo.com - December 1 at 4:59 PM
Analyzing Evogene (EVGN) and Calyxt (CLXT)Analyzing Evogene (EVGN) and Calyxt (CLXT)
www.americanbankingnews.com - November 30 at 8:06 AM
Zacks: Evogene Ltd. (EVGN) Given $8.00 Average Target Price by AnalystsZacks: Evogene Ltd. (EVGN) Given $8.00 Average Target Price by Analysts
www.americanbankingnews.com - November 28 at 7:56 AM
Evogene (EVGN) versus Calyxt (CLXT) Head to Head SurveyEvogene (EVGN) versus Calyxt (CLXT) Head to Head Survey
www.americanbankingnews.com - November 27 at 10:08 AM
Zacks: Analysts Expect Evogene Ltd. (EVGN) Will Announce Earnings of -$0.18 Per ShareZacks: Analysts Expect Evogene Ltd. (EVGN) Will Announce Earnings of -$0.18 Per Share
www.americanbankingnews.com - November 23 at 9:16 PM
Reviewing Calyxt (CLXT) & Evogene (EVGN)Reviewing Calyxt (CLXT) & Evogene (EVGN)
www.americanbankingnews.com - November 23 at 5:18 PM
Calyxt (CLXT) versus Evogene (EVGN) Financial ContrastCalyxt (CLXT) versus Evogene (EVGN) Financial Contrast
www.americanbankingnews.com - November 23 at 3:36 AM
Evogene (EVGN) and Calyxt (CLXT) Financial ComparisonEvogene (EVGN) and Calyxt (CLXT) Financial Comparison
www.americanbankingnews.com - November 23 at 3:12 AM
Evogene (EVGN) & Calyxt (CLXT) Financial ContrastEvogene (EVGN) & Calyxt (CLXT) Financial Contrast
www.americanbankingnews.com - November 21 at 12:06 PM
Head to Head Comparison: Calyxt (CLXT) versus Evogene (EVGN)Head to Head Comparison: Calyxt (CLXT) versus Evogene (EVGN)
www.americanbankingnews.com - November 21 at 11:20 AM
Calyxt (CLXT) and Evogene (EVGN) Head-To-Head SurveyCalyxt (CLXT) and Evogene (EVGN) Head-To-Head Survey
www.americanbankingnews.com - November 21 at 9:55 AM
Reviewing Evogene (EVGN) & Calyxt (CLXT)Reviewing Evogene (EVGN) & Calyxt (CLXT)
www.americanbankingnews.com - November 19 at 3:44 AM
Contrasting Calyxt (CLXT) & Evogene (EVGN)Contrasting Calyxt (CLXT) & Evogene (EVGN)
www.americanbankingnews.com - November 17 at 11:24 PM
Critical Review: Calyxt (CLXT) vs. Evogene (EVGN)Critical Review: Calyxt (CLXT) vs. Evogene (EVGN)
www.americanbankingnews.com - November 16 at 9:34 PM
Evogene Ltd (EVGN) Set to Announce Quarterly Earnings on WednesdayEvogene Ltd (EVGN) Set to Announce Quarterly Earnings on Wednesday
www.americanbankingnews.com - November 15 at 1:50 AM
Evogenes First Quarter 2016 Earnings Announcement ScheduleEvogene's First Quarter 2016 Earnings Announcement Schedule
www.thestreet.com - May 2 at 9:37 AM
Evogene reports 4Q lossEvogene reports 4Q loss
www.cnbc.com - March 1 at 2:48 PM
Evogenes Fourth Quarter And Full Year 2015 Earnings Announcement ScheduleEvogene's Fourth Quarter And Full Year 2015 Earnings Announcement Schedule
www.thestreet.com - February 9 at 12:05 PM
Insect-Beating Seeds Are Growth Engine for Evogene, CEO SaysInsect-Beating Seeds Are Growth Engine for Evogene, CEO Says
www.bloomberg.com - January 5 at 9:26 AM
CFO Moves: Benefitfocus Inc., EvogeneCFO Moves: Benefitfocus Inc., Evogene
blogs.wsj.com - December 22 at 4:51 PM

SEC Filings

Evogene (NASDAQ:EVGN) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Evogene (NASDAQ:EVGN) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Evogene (NASDAQ EVGN) Stock Chart for Sunday, February, 18, 2018

Loading chart…

This page was last updated on 2/18/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.